Research programme: multidrug-resistant infection therapeutics - Summit Therapeutics

Drug Profile

Research programme: multidrug-resistant infection therapeutics - Summit Therapeutics

Alternative Names: Antibiotics - Summit Therapeutics; DDS 01

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Discuva
  • Developer Summit Therapeutics
  • Class Anti-infectives; Antibacterials; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections; Gonorrhoea

Most Recent Events

  • 21 Apr 2018 Antimicrobial data and pharmacodynamics data from in-vitro studies in Gonorrhoea presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  • 13 Mar 2018 Summit Therapeutics intends to select a candidate from the gonorrhoea programme to enter into IND enabling studies in the second half of 2018
  • 13 Mar 2018 Early research in Gonorrhoea in United Kingdom (unspecified route) before March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top